Kumquat Biosciences

Kumquat Biosciences is a private, clinical-stage oncology biotech leveraging deep KRAS pathway expertise to develop small molecule inhibitors and combination therapies aimed at historically undruggable targets. The company has rapidly advanced its lead KRAS G12D inhibitor into Phase I clinical trials through a significant global collaboration with pharmaceutical giant Bayer. With a focus on targeted and immuno-oncology, Kumquat aims to address high-unmet-need cancers and overcome drug resistance.

KRAS pathway expertise focused on developing small molecule inhibitors and combination therapies that target undruggable KRAS mutations while engaging the immune system for synergistic effects.

The KRAS inhibitor field is highly competitive, with approved drugs for G12C and numerous clinical-stage programs targeting G12D from companies like Mirati Therapeutics (now Bristol Myers Squibb), Revolution Medicines, and others. Success will require demonstrating superior clinical profile in a crowded market.